PGNX - Progenics Pharmaceuticals Inc. Tue 21'st Feb 2017
Stock analysis for Tue 21'st Feb 2017 (Updated daily)
Buy candidate since 2017-02-16
Progenics Pharmaceuticals Inc. Stock Analysis
Progenics Pharmaceuticals Inc. fell by -1.69% in the last day, from USD 10.62 to USD 10.44. The price has been going up and down for this period, and there has been a 4.4% gain for the last 2 weeks. Volume fell in the last day along with the stock, which is actually a good sign as volume should follow the stock. In the last day the trading volume fell by -11.03 million shares and in total, 2.12 million shares bought and sold for approx. USD 22.14 million.
Progenics Pharmaceuticals Inc. lies in the upper part of a wide and strong rising trend in the short term, and this will normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break-up at the top trend line at USD 10.64 will firstly indicate a stronger raising rate. Given the current short-term trend, the stock is expected to rise 10.8% during the next 3 months and, with 90% probability hold a price between USD 9.50 and USD 11.79 at the end of this period.
Progenics Pharmaceuticals Inc. holds buy signals from both short- and long-term moving averages. In addition, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down there will be some support from the lines at USD 10.01 and USD 9.20. A break down below any of these levels will issue sell signals. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sales signal was issued from a pivot top point on Friday February 17, 2017, which indicates further falls until a new bottom pivot has been found. Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.
Relative Strength Index (RSI)
The stock holds a RSI14 at 73 and is currently being overbought on RSI. This does not have to be a sales signal as many stocks may go both long and hard while being overbought on the RSI. It is therefore important to evaluate the history of the share as it may tell you something about the RSI-sensitiveness.
Support & Resistance
On the downside, the stock finds support just below today's level from accumulated volume at USD 8.95 and USD 8.90. On the upside the stock meets some resistance just above today's level from accumulated volume at USD 10.54 and USD 10.62.
There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Progenics Pharmaceuticals Inc. finds support just below today's level at 8.95. If this is broken, then the next support from accumulated volume will be at 8.90 and 8.87. The stock is about to test the resistance from accumulated volume at USD 10.54 and this may cause the stock to take a minor break or get into a more sideways move for a few days.
This stock may move much during a day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved USD 0.54 between high and low, or 5.29%. For the last week, the stock has had a daily average volatility of 4.65%.
The stock is overbought on RSI14 and lies in the upper part of the trend. Normally this will pose a good selling opportunity for the short-term trader, but some stocks may go long and hard while being overbought. Regardless, the high RSI together with the trend position increases the risk and higher daily movements (volatility) should be expected. A correction down in the nearby future seems very likely and it is of great importance that the stock manages to break the trend before that occurs.
Our recommended stoploss: USD 9.96 (-4.60%) ( criteria: risk and position in trend)
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for this stock to perform well in the short-term. Due to some small weaknesses in the technical picture we have downgraded our recommendation for this stock since last evaluation from a Strong Buy Candidate to a Buy Candidate.